General
Preferred name
LEVOSALBUTAMOL
Synonyms
LEVALBUTEROL HYDROCHLORIDE ()
Xopenex ()
Levalbuterol (tartrate) ()
Levosalbutamol tartrate ()
LEVALBUTEROL TARTRATE ()
levalbuterol ()
Levosalbutamol sulfate ()
Levalbuterol (hydrochloride) ()
LEVALBUTEROL SULFATE ()
(R)-Albuterol (hydrochloride) ()
(R)-Salbutamol (hydrochloride) ()
Levosalbutamol (hydrochloride) ()
Levalbuterol hcl ()
Albuterol (r)-form hydrochloride ()
Levosalbutamol hydrochloride ()
Albuterol hydrochloride, r- ()
NSC-759255 ()
R-salbutamol ()
ASF-1096 ()
Albuterol (r)-form ()
Xopenex hfa ()
Levalbuterol sulphate ()
Salbutamol (hydrochloride) ()
P&D ID
PD013081
CAS
661464-94-4
34391-04-3
51022-70-9
148563-16-0
50293-90-8
Tags
drug candidate
natural product
drug
available
Approved by
FDA
First approval
1999
2005
Drug Status
investigational
approved
Drug indication
Bronchodilator
Asthma Prophylactic
Asthma
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS It acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
MOA β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.
INDICATION Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.
DESCRIPTION Levosalbutamol is a short-acting β2-adrenoceptor agonist used in anti-asthma medications. Structurally it is the R enantiomer of the racemic mixture that has the INN . Levosalbutamol belongs to the 'short-acting beta-agonist' (SABA) drug family. (GtoPdb)
DESCRIPTION Levalbuterol is a short-acting beta 2 adrenergic agonist. Levalbuterol binds to beta 2 adrenergic receptors and activates intracellular adenyl cyclase to promote the convertion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). It is used to treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). (BOC Sciences Bioactive Compounds)
Compound Sets
21
BOC Sciences Bioactive Compounds
levalbuterol-cas-34391-04-3-item-66610
Cayman Chemical Bioactives
23991
ChEMBL Approved Drugs
CHEMBL1201061
CHEMBL1002
CHEMBL3989693
ChEMBL Drugs
CHEMBL1201061
CHEMBL1002
CHEMBL3989693
CHEMBL3989589
Drug Repurposing Hub
DrugBank
DB13139
DrugBank Approved Drugs
DB13139
DrugCentral
1575
DrugCentral Approved Drugs
1575
DrugMAP
DM5YBO1
DrugMAP Approved Drugs
DM5YBO1
Enamine BioReference Compounds
Guide to Pharmacology
9816
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1002
MedChem Express Bioactive Compound Library
HY-B1675A
NCATS Inxight Approved Drugs
EDN2NBH5SS
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
levalbuterol-hydrochloride
TargetMol Bioactive Compound Library
T7164
External IDs
91
Properties
(calculated by RDKit )
Molecular Weight
239.15
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
1.31
TPSA
72.72
Fraction CSP3
0.54
Chiral centers
1.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Neuronal Signaling
GPCR/G protein
Target
??2-adrenergic receptor
ADRB2
Adrenergic Receptor
Indication
bronchospasm
MOA
Adrenergic Receptor agonist
Source data